SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: 2014 Report on the International Lemtrada - Forecast and Market Analysis to 2022

[January 21, 2014]

Research and Markets: 2014 Report on the International Lemtrada - Forecast and Market Analysis to 2022

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/658cql/lemtrada) has announced the addition of the "2014 Report on the International Lemtrada - Forecast and Market Analysis to 2022" report to their offering.

Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT (News - Alert)).

The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer's Betaseron/Betaferon (IFNß-1b), Biogen's Avonex (IFNß-1a) andMerck's Rebif (IFNß-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.


Lemtrada (alemtuzumab) is an IV-administered humanized mAb being investigated as a potential therapy for RRMS. Sanofi's and Genzyme's Lemtrada is currently being developed in collaboration with Bayer HealthCare, which has recently announced its intention to co-promote the drug for MS. It is approved under the trade name Campath as a monotherapy for the treatment of B-cell chronic lymphocytic leukemia (CLL). However, Sanofi's Genzyme unit recently decided to withdraw Campath from the US and EU markets in order to optimize the drug as a treatment for MS. By using a different dose and the trade name Lemtrada, the company is making a bid to stop physicians from prescribing the drug off-label for MS.

Key Topics Covered:

1 List of Tables and Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Opportunity and Unmet Need

7 Pipeline Assessment

8 Lemtrada (alemtuzumab)

9 Appendix

For more information visit http://www.researchandmarkets.com/research/658cql/lemtrada


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy